List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3888594/publications.pdf

Version: 2024-02-01



WELLINGLAU

#	Article	IF	CITATIONS
1	Novel intestinal dialysis interventions and microbiome modulation to control uremia. Current Opinion in Nephrology and Hypertension, 2022, 31, 82-91.	1.0	8
2	Artificial Intelligence Assessment of Renal Scarring (AIRS Study). Kidney360, 2022, 3, 83-90.	0.9	9
3	The consequences of altered microbiota in immune-related chronic kidney disease. Nephrology Dialysis Transplantation, 2021, 36, 1791-1798.	0.4	17
4	Cardiovascular and Bleeding Outcomes with Anticoagulants across Kidney Disease Stages: Analysis of a National US Cohort. American Journal of Nephrology, 2021, 52, 199-208.	1.4	8
5	The COVID-Kidney Controversy: Can SARS-CoV-2 Cause Direct Renal Infection?. Nephron, 2021, 145, 275-279.	0.9	10
6	Diabetes and the Gut Microbiome. Seminars in Nephrology, 2021, 41, 104-113.	0.6	17
7	Spectroscopic and deep learning-based approaches to identify and quantify cerebral microhemorrhages. Scientific Reports, 2021, 11, 10725.	1.6	1
8	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. Kidney International, 2021, 100, 1101-1111.	2.6	13
9	Insights Into the Mechanisms of Brain Endothelial Erythrophagocytosis. Frontiers in Cell and Developmental Biology, 2021, 9, 672009.	1.8	5
10	Controversies: Stroke Prevention in Chronic Kidney Disease. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105679.	0.7	4
11	Brain & Kidney 2020: Introduction to Special Issue. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105990.	0.7	0
12	Kidney Function Is Not Related to Brain Amyloid Burden on PET Imaging in The 90+ Study Cohort. Frontiers in Medicine, 2021, 8, 671945.	1.2	6
13	Cerebral Blood Flow in Chronic Kidney Disease. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105702.	0.7	6
14	Microbiome modulation as a novel therapeutic approach in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2021, 30, 75-84.	1.0	25
15	Using Digital Pathology to Identify and Quantify Cerebral Microhemorrhages. , 2021, , .		0
16	Chronic Kidney Disease Increases Cerebral Microbleeds in Mouse and Man. Translational Stroke Research, 2020, 11, 122-134.	2.3	51
17	Of Microbiomes and Microbleeds. Stroke, 2020, 51, 3489-3491.	1.0	0
18	Cystatin C, cognition, and brain MRI findings in 90+-year-olds. Neurobiology of Aging, 2020, 93, 78-84.	1.5	19

2.2

26

#	Article	IF	CITATIONS
19	Route of intestinal absorption and tissue distribution of iron contained in the novel phosphate binder ferric citrate. Nephrology Dialysis Transplantation, 2020, 35, 1136-1144.	0.4	2
20	A Case of Novel Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting with Gastroenteritis and Developing Severe Pulmonary Disease. American Journal of Nephrology, 2020, 51, 337-342.	1.4	93
21	Hemodynamic and Laboratory Changes during Incremental Transition from Twice to Thrice-Weekly Hemodialysis. CardioRenal Medicine, 2020, 10, 97-107.	0.7	1
22	Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC): Report of a Family Pedigree. American Journal of the Medical Sciences, 2020, 360, 724-727.	0.4	0
23	Development of zirconium-89 PET for imaging of alpha-klotho. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 95-105.	1.0	1
24	Gut microbial short-chain fatty acids and the risk of diabetes. Nature Reviews Nephrology, 2019, 15, 389-390.	4.1	29
25	Utility of Cardiac Biomarkers in the Setting of Kidney Disease. Nephron, 2019, 141, 227-235.	0.9	26
26	Impact of Gut Dysbiosis on Neurohormonal Pathways in Chronic Kidney Disease. Diseases (Basel,) Tj ETQq0 0 0	rgBT /Over 1.0	rlock 10 Tf 50
27	Ferric Citrate Attenuates Cardiac Hypertrophy and Fibrosis in a Rat Model of Chronic Kidney Disease. Iranian Journal of Kidney Diseases, 2019, 13, 98-104.	0.1	3
28	Dietary tetrahydrocurcumin reduces renal fibrosis and cardiac hypertrophy in 5/6 nephrectomized rats. Pharmacology Research and Perspectives, 2018, 6, e00385.	1.1	14
29	Urine mitochondrial DNA and diabetic nephropathy—a new frontier. Nephrology Dialysis Transplantation, 2018, 33, 719-721.	0.4	0
30	There's no place like home: 35â€year patient survival on home hemodialysis. Seminars in Dialysis, 2018, 31, 300-304.	0.7	8
31	Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins. Clinical Science, 2018, 132, 509-522.	1.8	147
32	The Phosphate Binder Ferric Citrate Alters the Gut Microbiome in Rats with Chronic Kidney Disease. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 452-460.	1.3	33
33	Phosphate Binder, Ferric Citrate, Attenuates Anemia, Renal Dysfunction, Oxidative Stress, Inflammation, and Fibrosis in 5/6 Nephrectomized CKD Rats. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 129-137.	1.3	17
34	Parathyroidectomy in the Management of Secondary Hyperparathyroidism. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 952-961.	2.2	147
35	Pharmacologic Blockade of αvβ1 Integrin Ameliorates Renal Failure and Fibrosis In Vivo. Journal of the American Society of Nephrology: JASN, 2017, 28, 1998-2005.	3.0	51
	Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis		

Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1118-1127.

#	Article	IF	CITATIONS
37	The Leaky Gut and Altered Microbiome in Chronic Kidney Disease. , 2017, 27, 458-461.		48
38	Warfarin Use and Increased Mortality in End-Stage Renal Disease. American Journal of Nephrology, 2017, 46, 249-256.	1.4	21
39	Effects of endâ€stage renal disease and dialysis modalities on blood ammonia level. Hemodialysis International, 2017, 21, 343-347.	0.4	8
40	Development and Validation of a Novel Laboratory-Specific Correction Equation for Total Serum Calcium and Its Association With Mortality Among Hemodialysis Patients. Journal of Bone and Mineral Research, 2017, 32, 549-559.	3.1	11
41	Urea, a true uremic toxin: the empire strikes back. Clinical Science, 2017, 131, 3-12.	1.8	88
42	The Cerebrovascular-Chronic Kidney Disease Connection: Perspectives and Mechanisms. Translational Stroke Research, 2017, 8, 67-76.	2.3	84
43	Hidden Hypercalcemia and Mortality Risk in Incident Hemodialysis Patients. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2440-2449.	1.8	26
44	Examining the robustness of the obesity paradox in maintenance hemodialysis patients: a marginal structural model analysis. Nephrology Dialysis Transplantation, 2016, 31, 1310-1319.	0.4	51
45	Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients. American Journal of Nephrology, 2016, 43, 85-96.	1.4	29
46	The Gut as a Source of Inflammation in Chronic Kidney Disease. Nephron, 2015, 130, 92-98.	0.9	346
47	Why Is the Association of Phosphorus and FGF23 with Mortality Stronger in African-American Hemodialysis Patients?. American Journal of Nephrology, 2015, 42, 22-24.	1.4	5
48	Uncorrected and Albumin-Corrected Calcium, Phosphorus, and Mortality in Patients Undergoing Maintenance Dialysis. Journal of the American Society of Nephrology: JASN, 2015, 26, 1671-1681.	3.0	72
49	Role of Nrf2 Dysfunction in Uremia-Associated Intestinal Inflammation and Epithelial Barrier Disruption. Digestive Diseases and Sciences, 2015, 60, 1215-1222.	1.1	67
50	High Amylose Resistant Starch Diet Ameliorates Oxidative Stress, Inflammation, and Progression of Chronic Kidney Disease. PLoS ONE, 2014, 9, e114881.	1.1	229
51	Risk of chronic kidney disease after cancer nephrectomy. Nature Reviews Nephrology, 2014, 10, 135-145.	4.1	56
52	Comparative Mortality–Predictability Using Alkaline Phosphatase and Parathyroid Hormone in Patients on Peritoneal Dialysis and Hemodialysis. Peritoneal Dialysis International, 2014, 34, 732-748.	1.1	45
53	Towards the revival of alkaline phosphatase for the management of bone disease, mortality and hip fractures. Nephrology Dialysis Transplantation, 2014, 29, 1450-1452.	0.4	8
54	Alkaline phosphatase: Better than <scp>PTH</scp> as a marker of cardiovascular and bone disease?. Hemodialysis International, 2014, 18, 720-724.	0.4	10

#	Article	IF	CITATIONS
55	Chronic Kidney Disease Results in Deficiency of ABCC6, the Novel Inhibitor of Vascular Calcification. American Journal of Nephrology, 2014, 40, 51-55.	1.4	29
56	Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients. Bone, 2014, 61, 201-207.	1.4	31
57	Impact of Age, Race and Ethnicity on Dialysis Patient Survival and Kidney Transplantation Disparities. American Journal of Nephrology, 2014, 39, 183-194.	1.4	63
58	Clinical Uses of 1-Alpha-Hydroxy-Ergocalciferol. Current Vascular Pharmacology, 2014, 12, 306-312.	0.8	8
59	Association of Serum Phosphorus Concentration With Mortality in Elderly and Nonelderly Hemodialysis Patients. , 2013, 23, 411-421.		44
60	Clinical Detection, Risk Factors, and Cardiovascular Consequences of Medial Arterial Calcification: A Pattern of Vascular Injury Associated With Aberrant Mineral Metabolism. Seminars in Nephrology, 2013, 33, 93-105.	0.6	45
61	Impact of age on survival predictability of bone turnover markers in hemodialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 2535-2545.	0.4	37
62	High phosphate feeding promotes mineral and bone abnormalities in mice with chronic kidney disease. Nephrology Dialysis Transplantation, 2013, 28, 62-69.	0.4	55
63	Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney International, 2013, 83, 1159-1168.	2.6	291
64	Sodium-Dependent Phosphate Cotransporters and Phosphate-Induced Calcification of Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2625-2632.	1.1	107
65	Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients. Kidney International Supplements, 2013, 3, 462-468.	4.6	34
66	Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney International, 2012, 82, 1261-1270.	2.6	228
67	Direct Effects of Phosphate on Vascular Cell Function. Advances in Chronic Kidney Disease, 2011, 18, 105-112.	0.6	103
68	Phosphate and vascular calcification: Emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thrombosis and Haemostasis, 2010, 104, 464-470.	1.8	102
69	Identification of two new members of the CSMD gene familyâ <sup>+</sup> . Genomics, 2003, 82, 412-415.	1.3	42
70	Kidney biopsy; challenges with peri-procedural management. Journal of Nephropathology, 0, , .	0.1	0